Prathyusha Konda ✨ (@labratprats) profile picture

DoD Postdoc @DanaFarber @harvardmed | Immunology, Genetics, Single-cell genomics | Rare kidney cancers | Artist @doodlephd

Boston, MA
Joined November 2013
Photo by Prathyusha Konda ✨ (@labratprats)Photo by Prathyusha Konda ✨ (@labratprats)Photo by Prathyusha Konda ✨ (@labratprats)Photo by Prathyusha Konda ✨ (@labratprats)Photo by Prathyusha Konda ✨ (@labratprats)Photo by Prathyusha Konda ✨ (@labratprats)Photo by Prathyusha Konda ✨ (@labratprats)Photo by Prathyusha Konda ✨ (@labratprats)Photo by Prathyusha Konda ✨ (@labratprats)Photo by Prathyusha Konda ✨ (@labratprats)
Update: Now published in @NatureComms, please check out our work, "Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma" w @srviswanathan @DrChoueiri @LabSignoretti @VanAllenLab @Cary_Weiss @DanaFarber_GU 🔗 lnkd.in/exzvuJeS
5
3
1
29
7,622
Prathyusha Konda ✨ retweeted
Congratulations @labratprats, @srviswanathan and the whole Viswanathan Lab and @DanaFarber_GU on another discovery in translocation RCC (TrRCC), a rare and aggressive kidney cancer. Using single-cell+spatial multi-omics, we show how TFE3 fusions drive distinct tumor programs. shaping an immunosuppressive microenvironment, including SPP1+ macrophages and dysfunctional T cells—This helps explain the limited activity of immunotherapy in TrRCC and pointing toward new biologically informed treatment strategies. @NatureComms @DanaFarber_GU
19
80
4,717
Prathyusha Konda ✨ retweeted
This is what a real Community looks like. Patients & Caregivers. Doctors & Clinicians. Researchers & Advocates. Different experiences. Different perspectives. But ONE shared purpose: To change the future of Kidney Cancer. Today, we came together with one voice because progress doesn’t happen in isolation. It happens when Patients share their experiences, Clinicians bring what they see every day, Researchers pursue the next breakthrough, and Advocates make sure those voices are heard. For me, THIS is what gives advocacy its power. We aren’t simply asking for Research Funding. We are showing what that Research can mean in someone’s life: Another treatment option, Another clinical trial, Another chance, Another tomorrow. There is incredible science happening in kidney cancer. Our job is to make sure it has the resources, collaboration and urgency needed to keep moving forward. One Community. One Voice. One Mission. More research. More options. More tomorrows. Proud to stand with the entire @KidneyCAN Community and everyone working to create a different future for people affected by kidney cancer. #KidneyCancer #KidneyCancerResearch #KidneyCAN #CancerResearch #PatientAdvocacy O
4
18
459
Prathyusha Konda ✨ retweeted
Very proud of our own @DanaFarber_GU superstar @MikeSerzanMD advocating for kidney cancer research. The @CDMRP grants managed within @DeptofWar have provided the backbone for bold ideas that led to significant understanding of the biology of kidney cancer! Glad to see also patient advocate extraordinaire @CJSTRAV3 + @elioibrahim8 @pablombarrios @AliHajjAli4 @LabSignoretti @NazliDizman + many others !
The progress we've made didn't happen by accident. It was made possible by researchers pursuing new discoveries, patients participating in research, and advocates making sure #KidneyCancer remains part of the conversation in Washington. That's why we're speaking up during KidneyCAN Advocacy Days, and why our advocacy continues long after these meetings are over. Join our advocacy community and help us keep pushing for progress in kidney cancer research. #AcceleratingCures
2
7
29
5,201
Prathyusha Konda ✨ retweeted
Single-cell sequencing of tRCC - a rare kidney cancer - found that it may create an environment that prevents immune cells from working effectively, inspiring future strategies to improve immune responsiveness in this cancer. Research by @srviswanathan @drchoueiri and @labratprats now in @NatureComms ➡️ bit.ly/45RpyGX. CC: @DanaFarber_GU
3
17
724
Prathyusha Konda ✨ retweeted
💯. We do not need a blackbox narrow minded automated prestige ranking system for any scientific work. 1/
I wanted to like QED's new 1% preprint ranking. But the more I looked at the data, the more uncomfortable it made me. Here is my full peer review: open.substack.com/pub/blekhm…
4
7
1
95
22,429
Prathyusha Konda ✨ retweeted
This paper took us 13 years and is one of the longest papers ever in Cell. Check it out & judge for yourself cell.com/cell/fulltext/S0092…
Replying to @JoinLifespan
Just because epigenetic drift follows a predictable pattern doesn't necessarily mean it's causal in aging. Predictable patterns can form from stochastic reactions. Also you cannot fix all extracellular damages with cellular rejuvenation. More here: olafurpall.substack.com/p/wh…
25
264
11
1,491
225,315
Prathyusha Konda ✨ retweeted
What are the key issues that have emerged on the @NatureMedicine time-of-day IO paper? 1. The clinical trial protocol uploaded to Nature was v1 dated Jan 2, 2022; however, the protocol includes references published in 2024. This calls into question when the protocol was written and if/when it was amended. 2. The clinicaltrials.gov record is concerning and calls into question whether the study was actually randomized. a. In the first record 9/2022, although the study was noted as randomized, the inclusion/exclusion criteria read as though it was a retrospective study, e.g., “First-line patients received immunological monotherapy or immunological combined chemotherapy” as an inclusion criteria and  “Lack of clinical diagnosis and treatment information or loss of follow-up” as an exclusion criteria. b. In the first record, the primary endpoint, sample size, treatment and ECOG criteria do not match what was in the protocol dated Jan 2, 2022.  c. On 3/19/2024, the study was changed from randomized/interventional to an observational case-control study d. It was not until 3/30/2024 (2 months before end of randomization) that the study was changed to the design described in the manuscript. 3. The OS K-M curve presented at ASCO had errors – i.e., the censor marks do not match the at-risk table. This raises concerns about the integrity of statistical analyses. 4. The shape of the PFS does not match expectations. With a 6-week scan schedule, one would expect a stair-step drop every 6 weeks when patients have their scheduled imaging. Their PFS curve does not – it is smooth. Of note, in an observational study, a PFS curve generally does not have a staircase look because scans are not performed on a regular set schedule. 5. The 95% CI for the lower bound of the median OS in the manuscript is NE. This is not possible as the median was estimated. There are inconsistencies in the p-values in Table 1 (Baseline Characteristics) Credit to Daniel Brickman, Amanda Nottke and David Swank for creating this list — and to @houndcl for first identifying several of these issues.
Impressive job of post-publication Twitter peer review on this paper! With the effect size appearing inexplicably massive, plus the many inconsistencies in study conduct and reporting, it’s safe to assume the “time-of-day IO” question still fully open. nature.com/articles/s41591-0…
12
68
16
227
184,775
Prathyusha Konda ✨ retweeted
Please check out our team's recent study on plasma epigenomic profiling in #translocationRCC 👇 now out in @jclinicalinvest . Grateful to the incredible team of collaborators on this project @SylvanBacaLab @DrChoueiri #FreedmanLab
Might this strategy diagnose other mutationally quiet cancers? Srinivas R. Viswanathan @srviswanathan & team @danafarber detect TFE3 translocation renal cell carcinoma (#tRCC) via epigenomic profiling in plasma with high accuracy, enabling non-invasive diagnosis and monitoring of this fusion-driven #kidney #cancer: doi.org/10.1172/JCI195725 The figure shows longitudinal tracking of the tRCC integrated epigenomic score (TIES) and ctDNA fraction in a patient with tRCC. SD, stable disease; PR, partial response; PD, progressive disease.
1
4
16
3,208
Prathyusha Konda ✨ retweeted
🚀 New preprint! The Human Cytokine Dictionary - 9.7M cells, 12 donors, 90 cytokines - our largest human single-cell perturbation atlas yet. Users can map cytokine activity in their own data. Huge thanks to Lukas, Sören, Larsen, Parse Bio & Seelig lab! 🔗 biorxiv.org/content/10.64898…
7
160
4
656
34,485
Prathyusha Konda ✨ retweeted
Tonight’s episode of @60Minutes will include a segment on the impact of federally funded science and recent cuts to science funding. Our lab’s development of base editing and prime editing and their clinical applications will be among the work described in the episode. paramountpressexpress.com/cb…
33
158
14
794
265,443
Prathyusha Konda ✨ retweeted
Here's our latest - a deep dive into myeloid mediated immunotherapy resistance in kidney cancer, pairing single cell meta-analysis with companion experiments (h/t @DrChoueiri + @BraunMDPhD collaborations) Congrats Kevin Bi et al! @DanaFarber @broadinstitute @ImmunityCP
5
33
4
145
41,268
Prathyusha Konda ✨ retweeted
We’ve been busy 🐝s! Happy to share 5️⃣new preprints from the lab: one-liners below 👇#translocationRCC #CancerResearch @danafarber_GU [0/6]
5
19
2
51
14,574
Prathyusha Konda ✨ retweeted
Only “five” papers this time from @srviswanathan lab @DanaFarber_GU @DanaFarber focusing on the most salient questions in “Translocation” Science with Translocation RCC as the application! @kidneycan @kcCURE @KidneyCancer @harvardmed #DANA9 @Shikha_Gupta68 @labratprats
We’ve been busy 🐝s! Happy to share 5️⃣new preprints from the lab: one-liners below 👇#translocationRCC #CancerResearch @danafarber_GU [0/6]
3
39
8,180
This work wouldn't have been possible without the incredible support of our co-authors — @DrChoueiri @LabSignoretti @VanAllenLab @Cary_Weiss — and the generosity of patients who donated their samples. Also, grateful to @srviswanathan for his unwavering mentorship and support.
1
1
4
247